Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006) - podcast episode cover

Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006)

Sep 09, 20177 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing.

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006) | The Beacon podcast - Listen or read transcript on Metacast